
    
      Part 1 and 2 (staged analysis): Single dose of study drugs [celecoxib, placebo] followed by 3
      days of blood draws as Period I; then after a wash-out phase, single dose of study drugs
      [CG100649 2mg and 8mg, celecoxib 200mg, placebo], followed by blood draws on 6 days and
      bi-weekly urine collections for 8 weeks.

      Part 3: Five-way cross-over of single doses of study drugs with a CG100649 single dose level
      as determined by part 1 and 2, celecoxib 200mg, naproxen 500mg, acetazolamide 250mg and
      placebo.
    
  